HER2 Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Alerts
• Clinical Trials
• Forums

Efficacy and Safety of the Proposed Biosimilar PERT-IJS Versus EU-Perjeta ® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
Condition:   HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Interventions:   Biological: PERT-IJS plus trastuzumab, carboplatin and docetaxel;   Biological: Perjeta plus trastuzumab, carboplatin and docetaxel Sponsor:   Biocon Biologics UK Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials

Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer
Conditions:   Hormone-receptor-positive Breast Cancer;   HER2-low Breast Cancer;   HER2-negative Breast Cancer Intervention:   Other: No drug Sponsor:   Daiichi Sankyo, Inc. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials

Efficacy and Safety of the Proposed Biosimilar PERT-IJS Versus EU-Perjeta ® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
Condition:   HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Interventions:   Biological: PERT-IJS plus trastuzumab, carboplatin and docetaxel;   Biological: Perjeta plus trastuzumab, carboplatin and docetaxel Sponsor:   Biocon Biologics UK Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials

Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer
Conditions:   Hormone-receptor-positive Breast Cancer;   HER2-low Breast Cancer;   HER2-negative Breast Cancer Intervention:   Other: No drug Sponsor:   Daiichi Sankyo, Inc. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials

Efficacy and Safety of the Proposed Biosimilar PERT-IJS Versus EU-Perjeta ® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
Condition:   HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Interventions:   Biological: PERT-IJS plus trastuzumab, carboplatin and docetaxel;   Biological: Perjeta plus trastuzumab, carboplatin and docetaxel Sponsor:   Biocon Biologics UK Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials

Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer
Conditions:   Hormone-receptor-positive Breast Cancer;   HER2-low Breast Cancer;   HER2-negative Breast Cancer Intervention:   Other: No drug Sponsor:   Daiichi Sankyo, Inc. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials

Efficacy and Safety of the Proposed Biosimilar PERT-IJS Versus EU-Perjeta ® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
Condition:   HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Interventions:   Biological: PERT-IJS plus trastuzumab, carboplatin and docetaxel;   Biological: Perjeta plus trastuzumab, carboplatin and docetaxel Sponsor:   Biocon Biologics UK Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials

Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer
Conditions:   Hormone-receptor-positive Breast Cancer;   HER2-low Breast Cancer;   HER2-negative Breast Cancer Intervention:   Other: No drug Sponsor:   Daiichi Sankyo, Inc. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials

Efficacy and Safety of the Proposed Biosimilar PERT-IJS Versus EU-Perjeta ® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
Condition:   HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Interventions:   Biological: PERT-IJS plus trastuzumab, carboplatin and docetaxel;   Biological: Perjeta plus trastuzumab, carboplatin and docetaxel Sponsor:   Biocon Biologics UK Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials

Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer
Conditions:   Hormone-receptor-positive Breast Cancer;   HER2-low Breast Cancer;   HER2-negative Breast Cancer Intervention:   Other: No drug Sponsor:   Daiichi Sankyo, Inc. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials

Efficacy and Safety of the Proposed Biosimilar PERT-IJS Versus EU-Perjeta ® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
Condition:   HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Interventions:   Biological: PERT-IJS plus trastuzumab, carboplatin and docetaxel;   Biological: Perjeta plus trastuzumab, carboplatin and docetaxel Sponsor:   Biocon Biologics UK Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials

Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer
Conditions:   Hormone-receptor-positive Breast Cancer;   HER2-low Breast Cancer;   HER2-negative Breast Cancer Intervention:   Other: No drug Sponsor:   Daiichi Sankyo, Inc. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials

Efficacy and Safety of the Proposed Biosimilar PERT-IJS Versus EU-Perjeta ® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
Condition:   HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Interventions:   Biological: PERT-IJS plus trastuzumab, carboplatin and docetaxel;   Biological: Perjeta plus trastuzumab, carboplatin and docetaxel Sponsor:   Biocon Biologics UK Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials